ReviewFrontiers in cardiovascular medicine2025
Dysregulated cellular metabolism drives atherosclerotic plaque progression: a multi-cellular perspective.
Review in Frontiers in cardiovascular medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Hexosamine Biosynthetic Pathway and Fatty Acid β-Oxidative Imbalance: A Key Mechanism by Which Abnormal Macrophage Lipophagy Promotes Atherosclerosis in Diabetes.Cardiovascular drugs and therapy · 2026Review
- The dual role of metabolic reprogramming in macrophage polarization in rheumatoid arthritis and coronary heart disease and the intervention strategy of traditional Chinese medicine.Frontiers in cardiovascular medicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Atherosclerosis (AS) is a chronic inflammatory disease that can lead to severe cardiovascular diseases, primarily characterized by the formation of plaques within arterial walls, resulting in vascular stenosis and hardening. Numerous studies have revealed the complex connection between dysregulated cellular metabolism, specifically metabolic reprogramming, and AS. However, a comprehensive understanding of metabolic reprogramming in AS and its potential as a therapeutic target still requires further exploration. This article provides a comprehensive review of the role of dysregulated cellular metabolism in AS, with a particular focus on the phenomenon of metabolic reprogramming in diseased cells. It discusses in detail the adjustments in lipid and glucose metabolism of macrophages, the metabolic responses of endothelial cells under blood flow shear stress, oxidative stress, and inflammatory stimulation, as well as the metabolic changes of smooth muscle cells during phenotypic transformation. Furthermore, it analyzes how these dysregulated cellular metabolism affect the development of AS. Additionally, the article outlines the mechanisms by which chemically synthesized drugs and Chinese patent medicines treat AS by regulating metabolic pathways, offering a new perspective for disease research and clinical treatment.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.